Anticancer Therapies – Products

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.

PerkinElmer, Inc. has launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple critical quality attributes of cell samples in a single automated workflow, including cell identity, quality and quantity.

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

CapnoPharm is proud to announce its selection as a finalist of the prestigious Reuters Pharma Europe Award 2022 for its Cancer drug delivery innovation - Capnodrug® - in the Health Entrepreneur Award category.

Avacta Group plc announces that the US Food and Drug Administration has granted Orphan Drug Designation to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

NDA Group announces the expansion of the NDA Advisory Board with the appointment of Jan Sjöberg MD, PhD, specialist in internal medicine and hematology and associate professor at Karolinska Institutet.

The clinical success of CAR T-cell therapy has spurred increased interest and investments in the advanced therapeutics industry.

T cell-mediated therapies, such as CAR-T or tumor-infiltrating lymphocytes therapies, hold promise to transform cancer treatment to be more personalized and effective. Cytokines have a fundamental role in T cell survival, expansion, and differentiation.

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD.